RenovoRx Raises $10M in Oversubscribed Private Placement for Phase III Runway
RenovoRx closed an oversubscribed private placement raising $10 million through issuance of 10.64 million common shares and 5.32 million revenue milestone warrants at $0.938 per share with 50% warrant coverage. Proceeds provide runway to complete pivotal Phase III TIGeR-PaC enrollment by mid-2026 and accelerate RenovoCath commercialization through 2027.
1. Private Placement Details
RenovoRx issued 10,638,790 common shares and attached 5,319,392 revenue milestone warrants at $0.938 per share in a private placement that closed March 20, 2026. The offering attracted new and existing institutional investors—including Transcend Partners, AIGH Capital, Bleichroeder and Pathfinder—and saw participation from senior management and board members at a premium price of $1.0288 per share.
2. Use of Proceeds and Development Milestones
Gross proceeds of $10 million, before expenses, will fund acceleration of RenovoCath commercial rollout and support completion of the pivotal Phase III TIGeR-PaC trial in locally advanced pancreatic cancer. Full enrollment is targeted by mid-2026 with final data expected in 2027, extending the company’s cash runway into key data readout and revenue growth phases.
3. Leadership and Investor Confidence
The financing underscores strong conviction in RenovoRx’s strategy, bolstered by the recent appointment of Mark Voll as CFO to scale commercial operations. Management highlights a nimble, capital-efficient commercial team and the transition of 16 trial sites into revenue-generating centers upon trial completion.